Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to enroll patients to support an expected study completion in 2026 Cash and investments of $20.4 million at December 31, 2025 Virtual investor and analyst day with business updates to be held on Monday, March 23, 2026 at 11:00 am ET SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2025 financial results and provided a corporate update.